GLP1R and atrial fibrillation: Furthermore, contemporary medications with improved safety profile may offer improved possibilities for control of AF, for example, with sodium-glucose co-transporter-2 inhibitors that may reduce risk of AF in T2DM,221 or with glucagon-like peptide-1 receptor agonists (except albiglutide222) that advantageously do not increase risk of AF in obese patients with DM.223